United States News Todas as matérias

Ripple is celebrating the rapid ascent of its RLUSD stablecoin into the top tier of regulated USD tokens, underscoring strong institutional adoption, regulatory alignment and growing global integration.

Former Alameda Research chief executive Caroline Ellison has been transferred from federal prison to a reentry facility ahead of an early release, highlighting her cooperation in the FTX case and renewed public attention on the exchange’s collapse.

VYNE Therapeutics (NASDAQ:VYNE) and Yarrow Bioscience have entered into a definitive all-stock merger agreement, with the combined company expected to operate under the name Yarrow Bioscience and trade on Nasdaq under the ticker YARW.

ABM Industries (NYSE:ABM) reported a fiscal fourth-quarter net income of $34.8 million, or 56 cents per share, recovering from a loss in the same period last year.

However, the company’s adjusted earnings, which exclude restructuring costs and expenses related to mergers and acquisitions, were 88 cents per share, missing Wall Street expectations.

General Mills (NYSE:GIS) reported its second-quarter results for the fiscal year 2025, showing a 7 percent decrease in net sales to $4.9 billion

Processa Pharmaceuticals (NASDAQ:PCSA) provided a Phase 2 clinical update for its combination therapy, NGC-Cap (PCS6422 + capecitabine), on December 17, 2025.

Vistagen (NASDAQ:VTGN) announced disappointing results from its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol, a treatment for social anxiety disorder.

The study failed to meet its primary endpoint, which was based on the change from baseline in the Subjective Units of Distress Scale (SUDS).

SCHMID Group (NASDAQ:SHMD) reported its unaudited H1 2025 financial results, revealing a significant decline in revenue to €16.9 million, compared to €29.7 million in the same period a year earlier.

Toro Co. (NYSE:TTC) reported a profit of $73 million for its fiscal fourth quarter, or 74 cents per share, beating Wall Street expectations.

Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.

The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.

Dyadic (NASDAQ:DYAI) has expanded its strategic collaboration with Fermbox Bio to enhance the manufacturing, commercialization, and dual-sourcing of animal-free proteins and enzymes developed by Dyadic.

NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.

Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.

Spire Global (NYSE:SPIR), a leading satellite data provider, reported a revenue decline for the third quarter of 2025, posting $12.7 million in sales, a drop from the same period last year.

Steel Dynamics (NASDAQ:STLD) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting a range of $1.65 to $1.69 per diluted share.

This represents a notable decline from the $2.74 per share earnings reported in the third quarter of 2025, but an increase over the $1.36 per share reported in Q4 2024.

Coursera (NYSE:COUR) and Udemy (NASDAQ:UDMY) announced today that they have entered into a definitive merger agreement to combine in an all-stock transaction valued at approximately $2.5 billion.

Wiley (NYSE:WLY), a global leader in scientific content and research intelligence, has announced a quarterly cash dividend of $0.355 per share, effective January 15, 2026.

Nucor (NYSE:NUE) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting earnings per share (EPS) in the range of $1.65 to $1.75.

Jabil (NYSE:JBL) has reported preliminary, unaudited financial results for the first quarter of fiscal year 2026, posting strong performance with net revenue of $8.3 billion.

The company's U.S. GAAP operating income stood at $283 million, and U.S. GAAP diluted earnings per share (EPS) was $1.35.

Texas Pacific Land Corporation (NYSE:TPL) has announced a strategic partnership with Bolt Data & Energy (Bolt) to develop large-scale data center campuses and the necessary infrastructure across TPL land.

Warner Bros. Discovery (NASDAQ:WBD) has announced that its Board of Directors has unanimously rejected the tender offer launched by Paramount Skydance (NASDAQ:PSKY) on December 8, 2025.

ABM (NYSE:ABM) has announced its agreement to acquire WGNSTAR in a cash transaction valued at approximately $275 million.

Sealed Air (NYSE:SEE) announced the expiration of the 30-day go-shop period under its definitive merger agreement with funds affiliated with Clayton, Dubilier & Rice (CD&R) on December 16, 2025.

Merck (NYSE:MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.